Comparative effectiveness among BRAF plus MEK inhibitors for patients with BRAF V600-mutant melanoma
Authors:
- G.K. InGIG.K. In
- K. ChenKCK. Chen
- G. SajeevGSG. Sajeev
- R. SimpsonRSR. Simpson
- S. KaliaSKS. Kalia
- D. ChristensenDCD. Christensen
- D. LiuDLD. Liu
- N. RezaiNRN. Rezai
- A. di PietroAPA. di Pietro
- J. SignorovitchJSJ. Signorovitch
Open Access
- 19 September 2024
- journal article
- Published by Elsevier in ESMO Real World Data and Digital Oncology
- Vol. 6
Abstract
No abstract availableKeywords
Funding Information
- Pfizer
This publication has 23 references indexed in Scilit:
- Comparative efficacy and safety of targeted therapies for BRAF-mutant unresectable or metastatic melanoma: Results from a systematic literature review and a network meta-analysisCancer Treatment Reviews, 2022
- Analysis of a Real-World Progression Variable and Related Endpoints for Patients with Five Different Cancer TypesAdvances in Therapy, 2022
- External control arms in oncology: current use and future directionsAnnals of Oncology, 2022
- Real‐world evidence to support regulatory decision‐making for medicines: Considerations for external control armsPharmacoepidemiology and Drug Safety, 2020
- Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600–Mutated Metastatic MelanomaJAMA Oncology, 2018
- Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trialThe Lancet Oncology, 2018
- Combining immunotherapy and targeted therapies in cancer treatmentNature Reviews Cancer, 2012
- Multiple imputation using chained equations: Issues and guidance for practiceStatistics in Medicine, 2010
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- The combination of randomized and historical controls in clinical trialsJournal of Chronic Diseases, 1976